E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/26/2012 in the Prospect News Convertibles Daily and Prospect News Liability Management Daily.

EDAP uses exchange offer of debentures, warrants to restructure debt

By Marisa Wong

Madison, Wis., Jan. 26 - EDAP TMS SA has negotiated an exchange with holders of its senior debentures and warrants in order to restructure its outstanding convertible debt, according to a news release.

Certain holders have agreed to exchange their outstanding senior debentures and warrants for $10 million of 9% non-convertible term notes due June 30, 2014, warrants to purchase 408,691 newly issued shares at an exercise price equal to the par value per share and 1,926,685 newly issued shares in the form of American Depositary Receipts.

Certain other holders have agreed to exchange a total of $500,000 of outstanding senior debentures and warrants for 22,186 newly issued shares and cash in a like amount.

Following the exchange, EDAP's total outstanding debt will be reduced to $10 million from $10.5 million with an extended maturity of June 30, 2014 instead of Oct. 29, 2012.

"We are particularly pleased with this exchange completed with our bond and warrant holders. It removes the short term debt burden by extending the maturity to 2014 and eliminates the potential dilution connected with our 2007 convertible bond," said chief executive officer Marc Oczachowski in the release.

"We believe the agreement strengthens EDAP's financial profile in an efficient and effective transaction and reduces some of our future financial obligations. We believe these agreements are in the best interests of all EDAP shareholders and serve as the foundation for the company to continue its growth and market development."

Rodman & Renshaw, LLC was the adviser for the exchange.

EDAP develops, produces and markets medical devices for the treatment of urological diseases and is based in Vaulx-en-Velin, France.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.